# Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma

> **NCT03074825** · PHASE1 · TERMINATED · sponsor: **Chipscreen Biosciences, Ltd.** · enrollment: 5 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Chiauranib

## Key facts

- **NCT ID:** NCT03074825
- **Lead sponsor:** Chipscreen Biosciences, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-05-09
- **Primary completion:** 2017-08-15
- **Final completion:** 2019-02-14
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** The results fell short of expectations.
- **Last updated:** 2019-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03074825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03074825, "Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03074825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*